Skip to content

NASDAQ · small · thesis board

DAWN Day One Biopharmaceuticals

Precision oncology portfolio

View race

Thesis

Editorial summary — not a primary filing

Precision oncology; ADC/solid tumor adjacency via partnered and owned assets context.

Next gate

2026-11-08EstimatedPh2 readout

Breast / solid tumor ADC update

87 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~11 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~413d)100%
Days to gate (87d)21%
Show math

$380M cash ÷ $28M/mo burn ≈ 413 days. Source: curated SEC quarter figures.

Cash $380M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokMRKPh3okZLABPh1ok

Risks

  • Indication expansion
  • Competition
  • Burn
  • Concentration

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05415709as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01